Spondyloarthropathies News

Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.

DESTIN, Fla. — Early treatment can provide patients with axial spondyloarthritis a better opportunity to achieve drug-free remission and slow disease progression, according to a speaker at the Congress of Clinical Rheumatology East 2022.

Nurse-led education for patients with rheumatoid arthritis or spondyloarthritis, who are beginning biologic disease-modifying antirheumatic drugs, is effective at changing behaviors to prevent adverse events, according to data.

The FDA has approved once-daily oral upadacitinib for the treatment of adults with active ankylosing spondylitis who are intolerant, or have had an inadequate response, to one or more TNF inhibitors.

Acute anterior uveitis in first-degree relatives of axial spondyloarthritis probands should trigger a screening for axial SpA, according to researchers in the Annals of the Rheumatic Diseases.

Patients with psoriatic arthritis or ankylosing spondylitis who received once daily upadacitinib 15 mg experienced improvements in pain measures through 1 year, according to data published in RMD Open.

Joint replacement in patients with inflammatory arthritis is often beset with pitfalls like disease flares and infectious complications, and up until recently, the emergence new treatments were rendering the current guidelines outdated.

The COVID-19 pandemic has wrecked “significant negative impacts” on pain, function and treatment accessibility for individuals with chronic musculoskeletal pain, according to a speaker at the 2022 OARSI World Congress.

Patients with rheumatic and musculoskeletal diseases should engage in both aerobic and strengthening exercises, aiming for at least moderate intensity, according to new EULAR recommendations.

March is Autoimmune Awareness Month, and rheumatology organizations have been using their reach and influence on social media sites to spread the word and help patients with autoimmune diseases find community.